- 関
- antithrombotic agent、fibrinolytic drug、thrombolytic、thrombolytic agent、thrombolytic drug、thrombolytics
WordNet
- a kind of pharmaceutical that can break up clots blocking the flow of blood to the heart muscle (同)thrombolytic_agent, clot buster
- a substance that exerts some force or effect
- a businessman who buys or sells for another in exchange for a commission (同)factor, broker
- any agent or representative of a federal agency or bureau (同)federal agent
- a representative who acts on behalf of other persons or organizations
- an active and efficient cause; capable of producing a certain effect; "their research uncovered new disease agents"
- how long something has existed; "it was replaced because of its age"
- a time of life (usually defined in years) at which some particular qualification or power arises; "she was now of school age"; "tall for his eld" (同)eld
- begin to seem older; get older; "The death of his wife caused him to age fast"
- make older; "The death of his child aged him tremendously"
PrepTutorEJDIC
- 『代理人』;周旋人 / 働き(作用)を起こすもの;作用物,薬剤 / (政府機関,特にFBI,CIAなどの)部員,機関員
- 〈U〉(一般に)『年齢』,寿命;〈C〉(個々の)『年齢』,年 / 〈U〉成年(おとなとしての資格・権利を得る年齢;通例18または21歳) / 〈U〉『老齢』;《集合的に》老人たち / 〈U〉(人生の)『一時期』;〈C〉世代(generation) / 〈U〉〈C〉《しばしばA-》(歴史上の)『時代』 / 〈C〉《話》長い間 / 年をとる,ふける;〈物が〉古くなる / 〈年〉'を'とらせる;〈物〉'を'古びさせる
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 急性肺塞栓症および下肢深部静脈血栓症における線溶（血栓溶解）療法 fibrinolytic thrombolytic therapy in acute pulmonary embolism and lower extremity deep vein thrombosis
- 2. ST上昇型心筋梗塞に対する線溶療法：治療開始 fibrinolytic therapy in acute st elevation myocardial infarction initiation of therapy
- 3. 急性虚血性脳卒中における経静脈的線維素溶解（血栓溶解）治療：治療的使用 intravenous fibrinolytic thrombolytic therapy in acute ischemic stroke therapeutic use
- 4. ST上昇型心筋梗塞における血栓溶解療法の特性および臨床試験 characteristics of fibrinolytic thrombolytic agents and clinical trials in acute st elevation myocardial infarction
- 5. 入院前の血栓溶解療法の効果 performance of prehospital fibrinolysis
English Journal
- Purification and characterization of tenerplasminin-1, a serine peptidase inhibitor with antiplasmin activity from the coral snake (Micrurus tener tener) venom.
- Vivas J1, Ibarra C1, Salazar AM1, Neves-Ferreira AG2, Sánchez EE3, Perales J2, Rodríguez-Acosta A4, Guerrero B5.
- Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.Comp Biochem Physiol C Toxicol Pharmacol.2016 Jan;179:107-15. doi: 10.1016/j.cbpc.2015.09.009. Epub 2015 Sep 28.
- A plasmin inhibitor, named tenerplasminin-1 (TP1), was isolated from Micrurus tener tener (Mtt) venom. It showed a molecular mass of 6542Da, similarly to Kunitz-type serine peptidase inhibitors. The amidolytic activity of plasmin (0.5nM) on synthetic substrate S-2251 was inhibited by 91% following t
- PMID 26419785
- Acquired bleeding disorders in the elderly.
- Kruse-Jarres R1.
- Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program.Hematology Am Soc Hematol Educ Program.2015 Dec 5;2015(1):231-6. doi: 10.1182/asheducation-2015.1.231.
- The hemostatic balance changes with advancing age which may be due to factors such as platelet activation, increase of certain clotting factor proteins, slowing of the fibrinolytic system, and modification of the endothelium and blood flow. Generally, this predisposes the elderly to thrombosis rathe
- PMID 26637727
- Impact of the Pla Protease Substrate α2-Antiplasmin on the Progression of Primary Pneumonic Plague.
- Eddy JL1, Schroeder JA1, Zimbler DL1, Bellows LE1, Lathem WW2.
- Infection and immunity.Infect Immun.2015 Dec;83(12):4837-47. doi: 10.1128/IAI.01086-15. Epub 2015 Oct 5.
- Many pathogens usurp the host hemostatic system during infection to promote pathogenesis. Yersinia pestis, the causative agent of plague, expresses the plasminogen activator protease Pla, which has been shown in vitro to target and cleave multiple proteins within the fibrinolytic pathway, including
- PMID 26438794
Japanese Journal
- Fibrinolytic enzyme from newly isolated marine bacterium Bacillus subtilis ICTF-1 : Media optimization, purification and characterization(ENZYMOLOGY, PROTEIN ENGINEERING, AND ENZYME TECHNOLOGY)
- Mahajan Prafulla M.,Nayak Shubhada,Lele Smita S.
- Journal of bioscience and bioengineering 113(3), 307-314, 2012-03-00
- … Fibrinolytic enzymes are important in treatment of cardiovascular diseases. … The present work reports isolation, screening and identification of marine cultures for production of fibrinolytic enzymes. … A potent fibrinolytic enzyme-producing bacterium was isolated from marine niches and identified as Bacillus subtilis ICTF-1 on the basis of the 16S rRNA gene sequencing and biochemical properties. …
- NAID 110009425320
- 抗凝固薬/抗血小板薬/血栓溶解薬 (特集 救急領域における循環器用薬の使い方) -- (救急現場で必要な循環器用薬)
- 菊島 公夫,長尾 健
- 救急医学 34(12), 1643-1646, 2010-11-00
- NAID 40017383406
- Cerebellar Hemorrhage Provoked by Combined Use of Nattokinase and Aspirin in a Patient with Cerebral Microbleeds
- Chang Yung-Yee,Liu Jia-Shou,Lai Shung-Lon,Wu Hsiu-Shan,Lan Min-Yu
- Internal Medicine 47(5), 467-469, 2008
- … Nattokinase is used as a health-promoting medicine for preventing thrombosis due to its fibrinolytic activity. … We suggest that nattokinase may increase risk of intracerebral hemorrhage in patients who have bleeding-prone cerebral microangiopathy and are receiving other antithrombotic agent at the same time. …
- NAID 130000079714
Related Links
- Tissue plasminogen activator (t-PA) and urokinase are the agents that convert plasminogen to the active plasmin, thus allowing fibrinolysis to occur. t-PA is released into the blood very slowly by the damaged endothelium of the blood vessels, ...
- Fibrinolytics may also be preferable in low-risk patients (i.e., patients with mortality risk < 4.0%) since PCI does not provide any mortality benefit over fibrinolytic therapy for these patients. Results of a recent study suggest that fibrinolytic agents ...
Related Pictures
★リンクテーブル★
| リンク元 | 「thrombolytic」「thrombolytic drug」「thrombolytic agent」「antithrombotic agent」「線維素溶解薬」 |
| 拡張検索 | 「antifibrinolytic agent」 |
| 関連記事 | 「agent」「age」「fibrinolytic」 |
「thrombolytic」
- adj.
- 血栓溶解の
- n.
「thrombolytic drug」
- 関
- antithrombotic agent、fibrinolytic agent、fibrinolytic drug、thrombolytic、thrombolytic agent、thrombolytics
「thrombolytic agent」
「antithrombotic agent」
「線維素溶解薬」
「antifibrinolytic agent」
「agent」
- n.
- 代行者、代理人。代理業者
- 政府職員、官吏
- ある後位をする人、ある作用をするもの。動員、動力因、作用因。(文法)動作主。科学的変化を起こさせるもの、薬品、～剤。病原体
- 関
- agonist、agonistic、attorney、delegate、drug、etiologic agent、fomes、fomites、mediator、pathogen、pathogenic、pharmaceutical preparation、vector、vehicle
「age」
- n.
- 年齢、歳
- v.
- 加齢する、熟成する
「fibrinolytic」
- adj.
- 線維素溶解性の、線維素溶解の、線溶の